Lunit

Lunit ROE

The Return on Equity (ROE) of Lunit (328130.KQ) as of Oct 16, 2026 is 7.71 %. In the previous year, Return on Equity (ROE) was -13.75 % — a change of -156.08% (higher).

ROE

7.71 %

YoY

-156.08%

Last updated:

In 2024, Lunit's return on equity (ROE) was 7.71 %, a -156.08% increase from the -13.75 % ROE in the previous year.

The Lunit ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
79.78 KRW
Jan 1, 2020
64.10 KRW
Jan 1, 2021
-3,615.79 KRW
Jan 1, 2022
1.10 KRW
Jan 1, 2023
-13.75 KRW
Jan 1, 2024
7.71 KRW
The Lunit ROE history
YEARROEYoY
7.71 %-156.08%
-13.75 %-1,353.79%
1.10 %-100.03%
-3,615.79 %-5,740.81%
64.10 %-19.66%
79.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lunit Stock analysis

What does Lunit do? Lunit Inc is a South Korean company headquartered in Seoul, operating within the Health Care sector. The company has 293 employees and went public on July 21, 2022, with its ticker listed as 328130.KQ and ISIN KR7328130000. Lunit provides software solutions for medical diagnostic imaging services, focusing on the development and supply of AI-powered medical software. Its offerings include cancer diagnostic aid solutions, cancer early detection solutions, and cancer risk prediction solutions. The company's technology leverages artificial intelligence to enhance diagnostic capabilities in healthcare settings. Lunit's website is www.lunit.io, where further information about its services and solutions can be accessed. The company operates in the Health Care industry, specifically targeting medical imaging and AI-driven diagnostic tools. As of the latest available data, Lunit is engaged in the development and commercialization of AI-based medical software, aiming to improve the accuracy and efficiency of cancer-related diagnostics. The firm's IPO date marks its transition to a publicly traded company, reflecting its growth and market position in the healthcare technology space. Lunit's focus on AI applications in medical imaging positions it as a key player in the digital health sector, particularly within the Korean market and beyond. The company's solutions are designed to support healthcare professionals in making more informed diagnostic decisions, potentially reducing the time and resources required for cancer detection and treatment planning. Lunit is one of the most popular companies on Eulerpool.

ROE Details

Decoding Lunit's Return on Equity (ROE)

Lunit's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Lunit's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Lunit's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Lunit’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Lunit stock

Return on Equity (ROE) of Lunit is 7.71 % in 2024.

Return on Equity (ROE) of Lunit changed from -13.75 % to 7.71 %, representing a -156.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Lunit since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Lunit with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Lunit

All Key Metrics — Lunit